Teva and Alvotech launch SIMLANDI in US for arthritis
This marks the first biosimilar launched under the strategic partnership between the two companies. SIMLANDI has been approved by the US Food and Drug Administration (FDA) as the
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer medications.